Motor Neurone Disease Clinical Trials 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.Expanded Access Protocol of BHV-0223 for Patients With Amyotrophic Lateral Sclerosis (ALS)
Conditions: Amyotrophic Lateral Sclerosis; ALS; Lou Gehrig Disease; Lou Gehrig's Disease; Lou-Gehrigs Disease; Motor Neuron Disease, Amyotrophic Lateral Sclerosis Intervention: Drug: Riluzole Sponsor: Biohaven Pharmaceuticals, Inc. Available (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 25, 2018 Category: Research Source Type: clinical trials
Expanded Access Protocol of BHV-0223 for Patients With Amyotrophic Lateral Sclerosis (ALS)
Conditions: Amyotrophic Lateral Sclerosis; ALS; Lou Gehrig Disease; Lou Gehrig's Disease; Lou-Gehrigs Disease; Motor Neuron Disease, Amyotrophic Lateral Sclerosis Intervention: Drug: Riluzole Sponsor: Biohaven Pharmaceutical Holding Company Ltd. Available (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 25, 2018 Category: Research Source Type: clinical trials
Open-label Study to Evaluate Safety, Tolerability and PK of BHV-0223 in ALS
Conditions: Amyotrophic Lateral Sclerosis; ALS; Lou Gehrig Disease; Lou Gehrig's Disease; Lou-Gehrigs Disease; Motor Neuron Disease, Amyotrophic Lateral Sclerosis Intervention: Drug: BHV-0223 Sponsors: Biohaven Pharmaceutical Holding Company Ltd.; Cognitive Research Corporation (CRC) Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 9, 2018 Category: Research Source Type: clinical trials
